

# Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/HE4C2F791677EN.html>

Date: March 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: HE4C2F791677EN

## Abstracts

Hypertrophic Cardiomyopathy (HCM) is a condition in which a portion of the heart becomes thickened without an obvious cause. This results in the heart being less able to pump blood effectively. Symptoms vary from none to feeling tired, leg swelling, and shortness of breath. It may also result in chest pain or fainting.

This report contains market size and forecasts of Hypertrophic Cardiomyopathy (HCM) Therapeutics in Global, including the following market information:

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Hypertrophic Cardiomyopathy (HCM) Therapeutics market was valued at 1062.8 million in 2021 and is projected to reach US\$ 1249.1 million by 2028, at a CAGR of 2.3% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Beta Adrenergic Blocking Agents Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hypertrophic Cardiomyopathy (HCM) Therapeutics include AstraZeneca, Concordia International, Gilead Sciences, Merck, Mylan, Novartis, Pfizer, Sanofi and Teva Pharmaceutical Industries. etc. In 2021, the global top five

players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hypertrophic Cardiomyopathy (HCM) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segment Percentages, by Type, 2021 (%)

Beta Adrenergic Blocking Agents

Calcium Channel Blockers

Antiarrhythmic Agents

Anticoagulants

Others

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

## Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

### North America

US

Canada

Mexico

### Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

### Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hypertrophic Cardiomyopathy (HCM) Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Hypertrophic Cardiomyopathy (HCM) Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca

Concordia International

Gilead Sciences

Merck

Mylan

Novartis

Pfizer

Sanofi

Teva Pharmaceutical Industries

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL HYPERTROPHIC CARDIOMYOPATHY (HCM) THERAPEUTICS OVERALL MARKET SIZE**

- 2.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players in Global Market
- 3.2 Top Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies Ranked by Revenue
- 3.3 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Players in Global Market

3.6.1 List of Global Tier 1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies

## **4 MARKET SIGHTS BY PRODUCT**

4.1 Overview

4.1.1 by Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Beta Adrenergic Blocking Agents

4.1.3 Calcium Channel Blockers

4.1.4 Antiarrhythmic Agents

4.1.5 Anticoagulants

4.1.6 Others

4.2 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

## **5 SIGHTS BY APPLICATION**

5.1 Overview

5.1.1 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2021 & 2028

5.1.2 Hospital Pharmacies

5.1.3 Retail Pharmacies

5.2 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

## 6 SIGHTS BY REGION

6.1 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028

6.3.2 US Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.3.3 Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.3.4 Mexico Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028

6.4.2 Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.4.3 France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.4.4 U.K. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.4.5 Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.4.6 Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.4.8 Benelux Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028



6.5.2 China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.5.3 Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.5.4 South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.5.6 India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

## 6.6 South America

6.6.1 By Country - South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028

6.6.2 Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.6.3 Argentina Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

## 6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028

6.7.2 Turkey Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.7.3 Israel Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

6.7.5 UAE Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, 2017-2028

## 7 PLAYERS PROFILES

### 7.1 AstraZeneca

7.1.1 AstraZeneca Corporate Summary

7.1.2 AstraZeneca Business Overview

7.1.3 AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings

7.1.4 AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)

7.1.5 AstraZeneca Key News

### 7.2 Concordia International

7.2.1 Concordia International Corporate Summary

- 7.2.2 Concordia International Business Overview
- 7.2.3 Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
- 7.2.4 Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
- 7.2.5 Concordia International Key News
- 7.3 Gilead Sciences
  - 7.3.1 Gilead Sciences Corporate Summary
  - 7.3.2 Gilead Sciences Business Overview
  - 7.3.3 Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  - 7.3.4 Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  - 7.3.5 Gilead Sciences Key News
- 7.4 Merck
  - 7.4.1 Merck Corporate Summary
  - 7.4.2 Merck Business Overview
  - 7.4.3 Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  - 7.4.4 Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  - 7.4.5 Merck Key News
- 7.5 Mylan
  - 7.5.1 Mylan Corporate Summary
  - 7.5.2 Mylan Business Overview
  - 7.5.3 Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  - 7.5.4 Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  - 7.5.5 Mylan Key News
- 7.6 Novartis
  - 7.6.1 Novartis Corporate Summary
  - 7.6.2 Novartis Business Overview
  - 7.6.3 Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  - 7.6.4 Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  - 7.6.5 Novartis Key News
- 7.7 Pfizer

- 7.7.1 Pfizer Corporate Summary
- 7.7.2 Pfizer Business Overview
- 7.7.3 Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
- 7.7.4 Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
- 7.7.5 Pfizer Key News
- 7.8 Sanofi
  - 7.8.1 Sanofi Corporate Summary
  - 7.8.2 Sanofi Business Overview
  - 7.8.3 Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  - 7.8.4 Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  - 7.8.5 Sanofi Key News
- 7.9 Teva Pharmaceutical Industries
  - 7.9.1 Teva Pharmaceutical Industries Corporate Summary
  - 7.9.2 Teva Pharmaceutical Industries Business Overview
  - 7.9.3 Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Major Product Offerings
  - 7.9.4 Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global Market (2017-2022)
  - 7.9.5 Teva Pharmaceutical Industries Key News

## **8 CONCLUSION**

## **9 APPENDIX**

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Opportunities & Trends in Global Market

Table 2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Drivers in Global Market

Table 3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Restraints in Global Market

Table 4. Key Players of Hypertrophic Cardiomyopathy (HCM) Therapeutics in Global Market

Table 5. Top Hypertrophic Cardiomyopathy (HCM) Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Type

Table 9. List of Global Tier 1 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Hypertrophic Cardiomyopathy (HCM) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics

Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Hypertrophic Cardiomyopathy (HCM)

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Hypertrophic Cardiomyopathy (HCM)

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics

Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics

Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics

Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics

Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hypertrophic Cardiomyopathy (HCM)

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hypertrophic Cardiomyopathy (HCM)

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM)

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM)

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. AstraZeneca Corporate Summary

Table 31. AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 32. AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Concordia International Corporate Summary

Table 34. Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 35. Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Gilead Sciences Corporate Summary

Table 37. Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 38. Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Merck Corporate Summary

Table 40. Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 41. Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. Mylan Corporate Summary

Table 43. Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 44. Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. Novartis Corporate Summary

Table 46. Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 47. Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 48. Pfizer Corporate Summary

Table 49. Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 50. Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 51. Sanofi Corporate Summary

Table 52. Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 53. Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 54. Teva Pharmaceutical Industries Corporate Summary

Table 55. Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Product Offerings

Table 56. Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue (US\$, Mn), (2017-2022)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Hypertrophic Cardiomyopathy (HCM) Therapeutics Segment by Type in 2021
- Figure 2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Segment by Application in 2021
- Figure 3. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue in 2021
- Figure 8. By Type - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
- Figure 12. US Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028
- Figure 16. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$,

Mn), 2017-2028

Figure 20. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. AstraZeneca Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Concordia International Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



Figure 39. Gilead Sciences Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Merck Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Mylan Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Novartis Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Pfizer Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Sanofi Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Teva Pharmaceutical Industries Hypertrophic Cardiomyopathy (HCM) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/HE4C2F791677EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HE4C2F791677EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

